Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T

Three things landing together is why this was not another “CAR-T concept talk”: KIR-CAR into humans, vaccine follow-up tied to survival, and CAR-T in people who do not yet have myeloma.